Norwalk Leslie V 4

What Happened Leslie V. Norwalk, a director of Neurocrine Biosciences (NBIX), sold 3,810 shares in open-market transactions on May 12, 2026. The weighted-average sales price was $155.01 per share, for total proceeds of approximately $590,601. This was a sale (not a purchase), and the filing indicates the trades were executed under a pre-established 10b5‑1 trading plan.

Key Details

• Transaction date: May 12, 2026 (Form 4 filed May 14, 2026) — filing appears timely (filed within two business days).
• Transaction type/code: Sale (S).
• Shares sold: 3,810; weighted-average price: $155.01; total value: ~$590,601.
• Price range: shares sold in multiple trades at $155.00 to $155.0550 (report includes a footnote offering per-price breakdown on request).
• Shares owned after transaction: Not specified in the provided Form 4.
• Footnotes: F1 — disposition executed by broker under a 10b5‑1 plan adopted September 15, 2025; issuer policy prevents amending the plan after adoption. F2 — weighted-average price noted; detailed per-trade breakdown available upon request.

Context Sales made under a 10b5‑1 plan are generally pre-planned and routine rather than an immediate signal of insider sentiment. This report documents a straightforward open-market sale by a director; no derivatives, option exercises, gifts, or tax-withholding events were reported in the disclosed transaction.